# TABLE of contents

### Relevance of mental illness

- Basic data .......................................................... 4
- Burden and costs of mental illness .................................. 5

### CIBERSAM. Who we are and what we do

- Organizational structure ............................................. 7
- CIBERSAM’s Research Programmes ................................ 8
- Transversal Platforms ................................................ 14
- CIBERSAM’s strategic vision: CIBERSAM’s mission, vision and values .................................................. 15
- CIBERSAM’s main outcomes ........................................ 16
- CIBERSAM and society ................................................. 17
- Contribution to the training of Mental Health researchers .......................................................... 19
- Public-private collaboration ........................................... 20
- International leadership ................................................ 21
- Contribution to the Roadmap for Mental Health Research in Europe: The ROAMER Project .................................................. 22
- Contribution to innovation in Mental Health .......................... 23

### Our Services Portfolio

- CIBERSAM collaboration opportunities ................................ 29
- Patronage ................................................................. 30
Relevance of mental illness in the world

The World Health Organisation (WHO) deems that around 700 million people in the world suffer from mental and neurological disorders. If we include alcohol and drug abuse, they represent 13% of the global morbidity burden.

One out of two persons will suffer from a mental disorder throughout his life (1).

Around 20% of the working population (in OCDE countries), suffers from any kind of light-moderate mental disorder of easy treatment such as anxiety or depression (1).

People with severe mental disorders die even 20 years before general population, have a higher unemployment rate and a lower purchasing power than general population (1).

It is deemed that up to 60% of patients that need a treatment are not receiving it (1).

In the world, suicide is the second more frequent cause of death among young people (2).

Mental disorders represent the main cause of early retirement and disability pensions (3).

25% of Spaniards suffer from at least one mental disorder throughout his life, which represents 5% of health cost

Data published within the framework of the World Mental Health Day 2012

---

(2) Proyecto de plan de acción integral sobre salud mental 2013-2020. OMS. 11 enero 2013
# Relevance of mental illness in the world

Mental Health is one of the areas with the highest cost, representing 5-18% of the total health cost (1).

- The costs of mental illness at the world level have been estimated in 2,493 thousand million dollars in 2010 (1).
- Both direct and indirect costs of mental illness in the European Union, may reach up to 4% of the GDP (1).
- The cost per capita of brain diseases in Europe was estimated in 1,550€ in 2010 (2).
- Mental illness is characterized by happening, in the majority, at the ages with a higher working activity, thus they are the second cause of temporary and permanent sick leave (3).

| Disease burden by age frames for different causes (disability-adjusted life years DALY) |
|----------------------------------|----------------------------------|
| ![Disease burden by age frames for different causes](image1.png) |

### Cost of mental illness

<table>
<thead>
<tr>
<th>Cost of brain diseases (thousand million euros)</th>
</tr>
</thead>
<tbody>
<tr>
<td>74,4 Anxiety disorders</td>
</tr>
<tr>
<td>93,9 Psychotic disorders</td>
</tr>
<tr>
<td>113,4 Mood disorders</td>
</tr>
<tr>
<td>13,9 Parkinson’s disease</td>
</tr>
<tr>
<td>64,1 Dementia</td>
</tr>
<tr>
<td>65,7 Addictions</td>
</tr>
<tr>
<td>105,2 Dementia</td>
</tr>
<tr>
<td>267,1 Other brain diseases</td>
</tr>
</tbody>
</table>

Mood, psychotic and anxiety disorders represent 35,3% of the cost derived from brain diseases

---

CIBERSAM 

Who we are

The Biomedical Research Networking Centre (CIBER) is a consortium attached to the National Institute of Health Carlos III (Ministry of Economy and Competitiveness). The CIBER’s area of Mental Health (CIBERSAM) is made up by 23 research groups in psychiatry, neuroscience and other disciplines related to Mental Health.

23 research groups from 7 Regions and 2 associated clinical groups

In 19 research centres of excellence.
450 researchers: 289 adjunct researchers, 54 research associates and 83 research employees.
Staff Percentages: Female 78%; Male 22%

- Basic, pre-clinical and clinical research groups.
- Groups selected on a competitive basis and assessed according to strict scientific quality criteria.

6 Scientific Programmes oriented to the most significant pathologies:

- Depression
- Schizophrenia
- Bipolar Disorder
- Therapeutic Innovation
- Child and Adolescent Mental Disorders
- Psychosomatic, Anxiety and Impulse Control Disorders
CIBERSAM Organisational structure

Direction and management bodies grant CIBERSAM’s management according to participation criteria, guaranteeing high quality standards.

CIBERSAM has a Scientific Advisory Board made up by international Mental Health research leaders that guarantees continuous advice in the development of its activities.

6 Scientific Programmes. Coordinator

| Depression | Dr. Víctor Pérez |
| Schizophrenia | Dr. Julio Sanjuán |
| Bipolar Disorder | Dr. Eduard Vieta |
| Therapeutic innovation | Dr. Francesc Artigas |
| Child and adolescent mental disorders | Dr. Josefina Castro |
| Psychosomatic, anxiety and impulse control disorders | Dr. Jose Manuel Menchón |

5 Transversal Platforms

| DNA Platform | Dr. Celso Arango |
| Brain Bank | Dr. José Javier Meana |
| GRIDSAM Shared Databases | Dr. Julio Sanjuán |
| Neuroimaging | Dr. Manuel Desco |
| Mental Health and Disability Instrument Library | Dr. Josep M. Haro |

4 Horizontal Programmes

| Quality Area | Training and Mobility Area | European Programmes Area | Institutional Relations Area |
| Dr. Ana González Pinto | Dr. Ángel Pazos | Dr. Jose Luis Ayuso | Dr. Julio Bobes |
Corporate dossier

Research programmes

Major Depression (MD) is a severe mental illness that affects around 6 million people in our country. Its lifetime prevalence is of 8.9% for men and 16.5% for women and its incidence has increased within the last decades.

What we do. Research lines

- Cellular and molecular basis of depression and of the action mechanism of antidepressant drugs. Intracellular signalling targets. Phenotypic and molecular characterization.
Schizophrenia is one of the most severe mental disorders and causes a high degree of disability, costs and family suffering. This disease affects around 400,000 Spaniards.

**What we do. Research lines**

- Studies on genetic, neurophysiological, neuroimaging and biochemical variables, in the early stages of psychosis.
- Studies on the neurological basis (genetic, neuroimaging and neurophysiology) of the different symptomatologic phenotypes of schizophrenia.
- Studies on neurobiological (neuroimaging, neurophysiology and cognitive) and clinical phenotypes of response to the different pharmacological treatments.
- Research on the efficiency and efficacy of psychotherapeutic treatments in combination with the usual pharmacological treatments of schizophrenia.
- Studies on the effects of schizophrenia on wealth, psychosocial adjustment, life quality, disability levels of the individual and in the patterns of services use by these patients and its impact on comorbidity.
**Bipolar Disorder** is a severe and highly prevalent mental illness. The programme groups are oriented to contributing to the knowledge development of the causes and treatment of the disease.

**What we do. Research lines**

- Determination of prevalence, incidence, comorbidity and disability associated to bipolar disorder.
- Study of bipolar disorder patients in the early stages of the disease and genetic and environmental factors associated to the staging of the disease.
- Analysis of the role of neurocognition and neuroimaging as endophenotype and potentially treatable prognostic factor.
- Validation of psychometric instruments for bipolar disorder.
- Research on biomarkers, drugs and psychosocial interventions for improving the treatment of bipolar disorder.
Transversal programme arose from the need of channelling CIBERSAM’s efforts towards the identification of new therapeutic targets and strategies. It develops translational and back-translational research, and works in the improvement of the existent experimental models of mental illness. It integrates basic and clinical research groups.

What we do. Research lines

- Design and assessment of new pharmacological and non-pharmacological treatment strategies.
- Study of the physiopathology of psychiatric disorders, including their genetic basis.
- Design of new diagnostic and therapeutic tools in experimental models of mental illness.
- Study of the neurobiological basis of resistance to treatments and the action mechanism of new therapeutic strategies.
At least 10% of children and adolescents present any kind of mental disorder and at least half of them have a significant reduction in their family, social and school performance. An even higher rate has clinical symptoms that interfere in their performance although not to the extent of fulfilling diagnostic criteria for a disorder.

**What we do. Research lines**

- Risk factors, genetic, clinical characteristics, neuroimaging, immunology, treatment and evolution of psychotic and affective disorders in children and adolescents.
- Risk factors, genetic, clinical characteristics, neuroimaging, immunology, treatment and evolution of eating disorders.
- Genetic, neuroimaging and immunological characteristics in children and adolescents with obsessive-compulsive and tic disorders.
- Genetic, neuroimaging characteristics, treatment and evolution of autism spectrum and other neurodevelopmental disorders.
- Safety and efficacy of psychotropic drugs and other treatments in children and adolescents.
Research programmes

Psychosomatic, anxiety and impulse control disorders

Research on psychosomatic, anxiety and impulse control disorders is focused on the eventual control of pathologies that, due to their high prevalence or to the intensity of their manifestations, have high social and life quality costs.

What we do. Research lines

• Aging, specifically healthy aging.
• Inflammation associated to stress and anxiety disorders.
• Longitudinal epidemiological studies and risk factors in medical populations.
• Anxiety and Obsessive-Compulsive Disorder (OCD).
• Neurobiological and psychosocial aspects of pain.
CIBERSAM has **5 transversal platforms** that support groups developing research in Mental Health, either attached to CIBERSAM or to other institutions. The platforms provide highly specialized equipment and staff.

### DNA Platform

**Coordinator:** Dr. Celso Arango

- DNA collection from patients with mental disorders (mainly schizophrenia, affective disorders and autism spectrum disorders), healthy relatives and control groups.
- The samples of genetic material are associated with detailed clinical data that allow the definition of the clinical stage of every case and the selection of the most appropriate samples for each study.

**+ 11,700 samples**

### Neuroimaging

**Coordinator:** Dr. Manuel Desco

- Platform for image storage and services for their processing.
- Meeting point between groups specialised in image processing and analysis within CIBERSAM.

**+ 11,500 images**

### Shared databases: GRIDSAM

**Coordinator:** Dr. Julio Sanjuán

- Tool for the systematized collection and centralized storage of structured and codified data from CIBERSAM’s multicentre projects.
- It allows the search of information in real time and of several projects simultaneously.
- Strategic element for collaborative projects.

**Access to more than 20,000 cases**

### Mental Health and Disability Instrument Library

**Coordinator:** Dr. Josep Maria Haro

- It includes tools for diagnosis, symptoms assessment, neuropsychology and measurement of disability, specific for special populations.
- It facilitates the access to questionnaires and additional documents through an electronic database of universal and free access.
- Meeting point for increasing the knowledge on tools development and validation techniques, exchange of advances and training on the main clinical, psychosocial functioning and neuropsychological scales.

**Access to more than 270 tools**

### Brain Bank

**Coordinator:** Dr. José Javier Meana

- It provides brain tissue samples of patients with mental disorder and of control groups as well as toxicology service for specific analysis.
- It includes donor clinical data and toxicological data.
- It is made up of 3 nodes: Sant Joan de Déu Foundation (integrated within the Biobanks Network – National Institute of Health Carlos III), the University of País Vasco and the University of Cantabria.

**More than 1,000 cases available**

---

**In development**

### CIBERSAM’s Clinical Trials Platform

- One-stop platform. Access to the most outstanding mental health research groups at the national level.
- High capacity of patients recruitment.
- Experimental studies in pre-clinical stages in different areas: genetics, neuroimaging, histological techniques, etc.
CIBERSAM carries out periodical strategic reflections, compiling its main action lines in triennial Strategic Plans. Besides the development of its strategic plans, CIBERSAM has an ambitious Quality Plan with measurable objectives and indicators which derives in agreed improvement areas. In alignment with its continuous quality and improvement policy, and as a key factor for the maintenance of its excellence, CIBERSAM carries out an annual assessment of its groups according to strict quality criteria, which acts as a basis for decision making concerning the allocation of funds and continuation in the centre.

CIBERSAM aims to contribute to the reduction of the impact and stigma of mental illness in the Spanish society. These objectives are performed through the creation and dissemination of scientific knowledge, the generation of health innovations, the training of mental health specialists with a research profile and the application of the advances into clinical practice and scientific-health policies.

CIBERSAM pursues to consolidate as a group network open to the scientific, health, policy community as well as to the general population, leader in Mental Health research, which generates knowledge and provides an added value and represents a reference for the creation of scientific policies in Mental Health at the national and European level.

- Competitiveness
- Translation and multidisciplinarity
- Collaboration
- Ethics
- Excellence
- Transparency
- Effectiveness
- Social commitment
- Innovation
Main results

Publications by CIBERSAM

1. **HIGHEST QUALITY AND IMPACT PUBLICATIONS**
   - More than 2,000 publications in first and second quartile journals in the last 5 years. CIBERSAM stands out specially for the high rate of first quartile publications.
   - More than 25 publications with an impact factor >15 in the last 5 years. CIBERSAM has published in high impact journals such as The New England Journal of Medicine, Nature, Lancet and Cell.

2. **COLLABORATION AND DEVELOPMENT OF JOINT PUBLICATIONS**
   - In the year 2014, more than half of the publications of CIBERSAM groups were joint publications.
   - In the last years, the rate of collaborative publications has significantly increased, many of them with participation of 3 or more groups.
   - In the period 2011-2014 CIBERSAM has developed collaborations with 6 other CIBER and 5 Networks for Cooperative Research in Health (RETICS).

3. **INTERNATIONAL COLLABORATION**
   - More than 685 publications in international collaboration within the last 5 years.

Innovation CIBERSAM

- Contributing to the transfer of knowledge 3 patents licenced by CIBERSAM, 1 in exploitation.
- Contributing to the introduction of innovation into clinical practice.
- Participation in the elaboration of Clinical Practice Guidelines. Some of them international.
- Contributing to promote new ways of communication and inter-relation with patients and families. CIBERSAM participates in the development of websites, apps and other online communication tools.
CIBERSAM works with the objective of translating research into new knowledge that allows the introduction of improvements in clinical practice which have an effect on a better mental health for everyone.

- **Members of CIBERSAM participate in the elaboration of Health Plans at the national and regional levels.**

- **CIBERSAM participates in the elaboration of clinical practice guidelines**

- **Development of dissemination books for patients and families.**
  - Guide *Piensa* (Think) for adolescents and families who wish to understand and face up to psychosis.
  - Guide for brothers/sisters of patients with psychotic symptoms.

- **Destigmatizing campaigns**

CIBERSAM takes special care of the relationship with society, maintaining a high level of commitment with the dissemination of research results and the conduction of need-based research.

It organizes an annual **Social Forum** that brings together representatives from the most important patients' associations and families with CIBERSAM’s researchers every year.

CIBERSAM commits for the strengthening of its presence in social media as a means for favouring the contact with society.

CIBERSAM is present at:

- **Twitter** [@CIBER_SAM](http://twitter.com/CIBER_SAM)
- **Facebook** [www.facebook.com/CIBERdeSaludMental](http://www.facebook.com/CIBERdeSaludMental)
- **LinkedIn** [www.linkedin.com/company/cibersam---centro-de-investigacion-en-red-de-salud-mental](http://www.linkedin.com/company/cibersam---centro-de-investigacion-en-red-de-salud-mental)
CIBERSAM and society

CIBERSAM is aware of the importance and increasing demand of the application of new technologies in the relationship of the patient with the health system, and the possibilities it offers for the development of new models of practice, follow up and control of the treatment. CIBERSAM collaborates and/or leads projects aimed to the creation of webs or Apps.

- Websites for patients and families
- Blogs and forums for sharing experiences
- On line training for professionals

This Web arose with the aim of facilitating medical visits to patients with autism spectrum disorders by providing information to patients on the most frequent processes.
http://www.doctortea.org/

Web targeted to patients with bipolar disorder and families. It provides a description of the disease and its symptoms, puts in touch specialist psychiatrists with patients and families...
http://www.puedoser.es/

Web of support to the patients with psychosis that provides specialised information, medical orientation and support to persons with auditory hallucinations and schizophrenia.
http://vocesenlacabeza.com/

Web that compiles the advantages of the use of clozapine, key milestones in research on this drug, how to use it and monitor patients, etc.
http://clozapinacomo opcion.es/

Interactive programme for patients that aims to put science and research to the service of society.
http://www.forumclinic.org/es/esquizofrenia

Web that provides information on the role of training activities for health or other disciplines professionals in the prevention of suicide in Spain.
http://prevencionsuicidio.com/

Self-help programme based on Cognitive Behavioural Therapy complementary to the usual treatment in mild or moderate depression. It consists of 6 packages + 3 optional with practical exercises and assessment of depression symptoms.
https://ifightdepression.com/es/
Contribution to the training of mental health researchers

Since its inception, CIBERSAM has a Training Programme in mental health and neuroscience translational research that aims to reduce the breach existent between clinical intervention in mental health and clinical and basic research in neuroscience.

CIBERSAM’s Training Programme

1. Inter-university Master in introduction to Mental Health Research
   CIBERSAM organizes the first Master in Mental Health Research of Spain which makes it a national reference.
   - Organized by the University of Cantabria, University Complutense of Madrid, University Autónoma of Barcelona, University of Barcelona and the University of Cádiz.
   - Face-to-face and on line courses.
   - 133 ECTS: Obligatory modules (39 ECTS); Optional modules (94 ECTS).
   - Functioning since school year 2013-2014.
   - Updated offer at [http://cibersam.es/cibersam](http://cibersam.es/cibersam)

2. CIBERSAM Training courses
   - Priority courses
   - Other courses of interest
   - In the last year CIBERSAM has funded grants for 23 researchers and has organized 46 of the 68 courses included in the programme.
   - Mention shall be made to the courses in psychotherapy, basic research assessment scales, neuroscience, data processing and accreditation for animal research activities.
   - Updated offer at [http://cibersam.es/cibersam](http://cibersam.es/cibersam)

3. Research stays
   - National
   - International
   - CIBERSAM researchers may apply for placements or rotations.
   - Stays and rotations are funded when they are relevant for researchers and their group’s curriculum.
   - During the last 6 years, more than 69 visits of researchers.

4. Dissemination and on line training
   - Access to training in specific areas of Mental Health.
   - Puedoser (I can be). Information on bipolar disorder according to the psychoeducative model of the disease applied to social media. [http://www.puedoser.es/](http://www.puedoser.es/)
CIBERSAM maintains collaborations with more than 30 companies in different projects. Some of the most significant collaborations of the last years are:

<table>
<thead>
<tr>
<th>Collaboration Area</th>
<th>Collaborating Companies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development of clinical trials and R&amp;D&amp;I projects</td>
<td>AstraZeneca, Lilly</td>
</tr>
<tr>
<td>Development of patients’ data recording, collection and analysis systems</td>
<td>AB BIOTICS, Lilly</td>
</tr>
<tr>
<td>Development of webs, platforms, apps for professionals, patients and families and general public</td>
<td>ADAMED, Lilly, AlmaIT, Nlife, ORDESA</td>
</tr>
</tbody>
</table>
In the last years, CIBERSAM has consolidated its position and visibility at the European and international levels, participating in the main European Mental Health Research Networks. This international leadership is represented in different actions carried out during the last years.

- **Clinical trials**: Participation in clinical trials at the European level.
- **Consortiums**: Participation and coordination in international consortiums and networks.
- **Healthy aging strategies**: Participation in the group for the Prevention of functional decline and frailty within the Commitment to the Action Plans of the *European Innovation Partnership on Active and Healthy Ageing*.
- **Accredited by the WHO**: Several CIBERSAM groups are accredited as collaborators of the mental health services network, both in the field of research and training.
- **Stays and collaborations**: CIBERSAM hosts researchers from international centres for research stays and PhD programmes. CIBERSAM researchers usually publish together with the most significant research groups at the European level.
- **International meetings**: Organization of the International Forum on new approaches in the treatment of schizophrenia.
- **Translation into Spanish of the DSM5**.
Contribution to the Roadmap for Mental Health Research in Europe. ROAMER project

**ROAMER objectives**
Analyze knowledge gaps, define the most necessary and relevant advances and establish a list of research priorities in the different Mental Health areas for the European Commission.

**Participant countries** Spain, France, Germany, Hungary, Italy, Netherlands, Nordic Countries and United Kingdom.

Through the coordination of this project, CIBERSAM is contributing in a decisive way to the definition of priority areas where more efforts shall be done in mental health research within the next years.

- Within the framework of the ROAMER project a big number of coordination activities and workshops have been celebrated, promoted by CIBERSAM with the participation of the main opinion leaders at the European and international levels.
- CIBERSAM shows a strong alignment with international trends, placing itself as a leader organization in Europe and participating actively in the definition of scientific European policies in the next years.

CIBERSAM organized a Meeting with the WHO and the NIH on future trends in mental disorders research diagnosis criteria in Madrid in February 2014.

Close to the end of the project, conclusions have been presented in the European Parliament in January 2015.
Contribution to **innovation** in Mental Health

CIBERSAM works for contributing to innovation in Mental Health

- Studies focused on a better knowledge of neurochemistry/ neurobiology underlying mental illness: Studies on neurotransmitters, receptors and intracellular signalling mechanisms.
- Studies focused on the improvement of knowledge on schizophrenia brain circuits.
- Studies on the action mechanism of antipsychotic drugs and new antidepressant strategies.
- Studies on the role of stress and inflammatory genes in psychiatric disorders.
- Knowledge of neurobiological mechanisms of hallucinations and sensitivity to psychototropic drugs.
- Knowledge of the genetic basis of mental illness.
- Neuroimaging studies (clinical and pre-clinical studies).
- Development of scales and new classifications.
- Increase of the number of patent applications by CIBERSAM’s researchers.
<table>
<thead>
<tr>
<th>R&amp;D&amp;I. Studies, projects and products</th>
<th>Depression</th>
<th>Schizophrenia</th>
<th>Bipolar Disorder</th>
<th>Therapeutic Innovation</th>
<th>Child and adolescent Mental Disorders</th>
<th>Psychosomatic, anxiety and impulse control disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic/translational research projects</td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
</tr>
<tr>
<td>Clinical research projects/Clinical trials</td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
</tr>
<tr>
<td>Health Technologies Assessment</td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
</tr>
<tr>
<td>Proof of concept, prototypes</td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
</tr>
<tr>
<td>Development of new diagnostic methods</td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
</tr>
<tr>
<td>Development of patients databases or records</td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
</tr>
<tr>
<td>Participation in health outcomes studies</td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
</tr>
<tr>
<td>Development of tools, scales, questionnaires</td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
</tr>
<tr>
<td>Development of sectorial studies, positioning reports, R&amp;D needs, support to health and R&amp;D policies</td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
</tr>
<tr>
<td>Economic assessment studies</td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
</tr>
<tr>
<td>Development of software, webs, apps</td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
<td><img src="active.png" alt="Active" /></td>
</tr>
</tbody>
</table>
## Our Services Portfolio

### Techniques and services

<table>
<thead>
<tr>
<th>Description</th>
<th>Depression</th>
<th>Schizophrenia</th>
<th>Bipolar Disorder</th>
<th>Therapeutic innovation</th>
<th>Child and adolescent Mental Disorders</th>
<th>Psychosomatic, anxiety and impulse control disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development of experimental models and behavior studies with experimental animals</td>
<td>⚫</td>
<td></td>
<td></td>
<td>⚫</td>
<td>⚫</td>
<td>⚫</td>
</tr>
<tr>
<td>Development of microscopy and neuroimaging techniques</td>
<td>⚫</td>
<td></td>
<td></td>
<td></td>
<td>⚫</td>
<td></td>
</tr>
<tr>
<td>Neurobiological methodologies: stereotactic surgery, microdialysis, intracellular signaling, etc.</td>
<td>⚫</td>
<td>⚫</td>
<td></td>
<td></td>
<td>⚫</td>
<td></td>
</tr>
<tr>
<td>Development of histological techniques</td>
<td>⚫</td>
<td></td>
<td></td>
<td></td>
<td>⚫</td>
<td></td>
</tr>
<tr>
<td>Radiometric techniques: binding/receptors and functional autoradiograph and <em>in situ</em> hybridization</td>
<td>⚫</td>
<td></td>
<td></td>
<td></td>
<td>⚫</td>
<td></td>
</tr>
<tr>
<td>Development of <em>in vivo</em> interference RNA strategies</td>
<td>⚫</td>
<td></td>
<td>⚫</td>
<td></td>
<td>⚫</td>
<td></td>
</tr>
<tr>
<td>Genetic studies including pharmacogenomics and gene-environment interaction</td>
<td>⚫</td>
<td></td>
<td></td>
<td></td>
<td>⚫</td>
<td></td>
</tr>
<tr>
<td>Electrophysiological techniques: activity record</td>
<td>⚫</td>
<td></td>
<td></td>
<td></td>
<td>⚫</td>
<td></td>
</tr>
</tbody>
</table>

**Key:**
- ⚫ Active actions
- ⚫ Actions in development
### Our Services Portfolio

<table>
<thead>
<tr>
<th>Health and clinical practice plans</th>
<th>Depression</th>
<th>Schizophrenia</th>
<th>Bipolar Disorder</th>
<th>Therapeutic innovation</th>
<th>Child and adolescent Mental Disorders</th>
<th>Psychosomatic, anxiety and impulse control disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development of clinical practice guidelines, best practice studies</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Development of aging and chronic patients assistance plans</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Projects oriented to the optimization of clinical processes/organizational improvements</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Support in innovative public purchase processes</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Training

| Organization of training actions                                      | ●          | ●             | ●                | ●                      |                                       |                                                     |
| Conducting of PhDs, industrial PhDs, internships in CIBERSAM’s groups | ●          | ●             | ●                | ●                      |                                       |                                                     |
| Development of on line training tools                                 | ●          | ●             | ●                | ●                      |                                       |                                                     |

- **Active actions**
- **Actions in development**
## Corporate dossier

### Our Services Portfolio

<table>
<thead>
<tr>
<th>DNA Platform</th>
<th>Neuroimaging</th>
<th>Shared Databases: GRIDSAM</th>
<th>Mental Health and Disability Instrument Library</th>
<th>Brain Bank</th>
<th>Clinical Trials</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Techniques and Services</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neuroimaging processing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Technical support for the installation of processing tools</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creation and development of new neuroimaging tools</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consultancy on image analysis and quantification methods</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Support for the management of collaborative research projects</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toxicological analysis in brain tissue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Determination of samples quality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Support in technical procedures for extraction, storage and management of DNA samples</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methodological support in the design of Mental Health research studies and projects</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recruitment of patients for clinical trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conducting of Mental Health Clinical Trials and methodological advice</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Active actions
- Actions in development
## Our Services Portfolio

<table>
<thead>
<tr>
<th>Access to information and samples</th>
<th>DNA Platform</th>
<th>Neuroimaging</th>
<th>Shared Databases: GRIDSAM</th>
<th>Mental Health and Disability Instrument Library</th>
<th>Brain Bank</th>
<th>Clinical Trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Access to patients and control groups samples banks</td>
<td>✔️</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✔️</td>
</tr>
<tr>
<td>Questionnaires and Mental Health metrics instruments</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✔️</td>
<td></td>
</tr>
<tr>
<td>Images for quantitative analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✔️</td>
</tr>
<tr>
<td>Acquisition of animal image</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Access to socio-demographic, clinical and research information</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✔️</td>
<td></td>
</tr>
<tr>
<td>Training</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Training actions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✔️</td>
</tr>
<tr>
<td>Training stays</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✔️</td>
</tr>
</tbody>
</table>

- ✔️ Active actions
- Actions in development
R&D&I Collaborations

- Innovation in drugs
- Innovation in diagnostic techniques
- Image technologies
- Technological development
- Health products assessment
- Records
- Software development
- Webs, apps

Collaboration in training actions

- Alliances with universities
- Collaboration with hospitals
- Collaboration with other CIBER and RETICS
- Sponsorship of courses, conferences, workshops, etc.

Collaboration with the Spanish National Health System

- Health/ Mental health Plans
- Process and organization improvement
- Positioning reports
- Economic assessment
- Clinical Practice and Best Practice Guidelines

Sponsorship Opportunities

- Congresses
- Courses
- Master
- Stays
- Chairs
- Workshops
- Conferences
- Seminars
- Clinical Practice Guidelines
- Books
- Awareness campaigns
- Transfer reports
Patronage CIBERSAM

If you wish to collaborate with the maintenance of CIBERSAM activities, you can make a donation through our website

www.cibersam.es

You can contribute to CIBERSAM by participating in the funding of:

1. CIBERSAM’s general activities
   - Research groups
   - Scientific programmes
   - Research lines

2. Dissemination
   - Dissemination of research and clinical results
   - Events
   - Campaigns in the media

3. Training
   - Master
   - Courses
   - Researchers’ stays and mobility
The Biomedical Research Networking Centre (CIBER) is a consortium attached to the National Institute of Health Carlos III (Ministry of Economy and Competitiveness). The CIBER’s area of Mental Health (CIBERSAM) is made up by 23 research groups in psychiatrics, neuroscience and other disciplines related to Mental Health.

Access to 23 clinical and basic research groups, of excellence, in the Regions

In 19 research centers of excellence.
450 researchers: 289 assistant researchers, 54 research associates and 83 research employees.

CIBERSAM has 5 transversal platforms with highly specialized equipment and staff.

DNA Platform
Coordinator: Dr. Celso Arango

Neuroimaging
Coordinator: Dr. Manuel Desco

Mental Health and Disability Instrument Library
Coordinator: Dr. Josep Maria Haro

Brain Bank
Head: Dr. José Javier Meana

CIBERSAM Clinical Trials Platform

6 Scientific Programmes oriented to the most relevant pathologies:
- Depression
- Schizophrenia
- Bipolar Disorder
- Therapeutic Innovation
- Child and adolescent psychiatry
- Psychosomatic, anxiety and impulse control disorders
**Our capacities**

**Research**
- Basic groups
  - Basic
- Pre-clinical
- Clinical

**Clinical groups**
- Clinical

**Providers of research services**
- Development of diagnostic technologies

**Development of drugs:**
- Advice on clinical trial design. Identification of high interest populations as focus of the development of clinical trials.
- Access to clinical groups in 10 hospitals at the national level.
- Access to patients cohorts for clinical trials with patients groups of interest.

**ACCESS TO GROUPS OF EXCELLENCE**
Groups selected in a competitive basis and assessed according to strict scientific quality criteria.

**CIBERSAM CLINICAL TRIALS PLATFORM**

**SCIENTIFIC AND CLINICAL LEADERSHIP**
Leadership in the definition of priorities of R&D and clinical innovation, clinical protocols, etc.

---

**CLINICAL TRIALS PLATFORM**

- **1. H Marqués de Valdecilla (Santander)**
- **2. H Álava (Vitoria)**
- **3. H Clínic (Barcelona)**
- **4. H Sant Joan de Deu (Barcelona)**
- **5. H Bellvitge (Barcelona)**
- **6. H Sant Pau (Barcelona)**
- **7. FIDMAG (Centros Germanes Hospitalàries-Cataluña)**
- **8. H U Ramón y Cajal (Madrid)**
- **9. HGU Gregorio Marañón (Madrid)**
- **10. HU La Princesa (Madrid)**
- **11. H Clínic San Carlos (Madrid)**

Hospital Universitari Vall d’Hebron (clínico vinculado)
Hospital Universitari Institut Pere Mata (clínico vinculado)